WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317323

CAS#: 41859-67-0

Description: Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity. Bezafibrate is a fibrate drug used for the treatment of hyperlipidaemia. Bezafibrate decreases triglyceride levels, increases high density lipoprotein cholesterol levels, and decreases total and low density lipoprotein cholesterol levels. It is commonly marketed as Bezalip.

Chemical Structure

CAS# 41859-67-0

Theoretical Analysis

MedKoo Cat#: 317323
Name: Bezafibrate
CAS#: 41859-67-0
Chemical Formula: C19H20ClNO4
Exact Mass: 361.10809
Molecular Weight: 361.82
Elemental Analysis: C, 63.07; H, 5.57; Cl, 9.80; N, 3.87; O, 17.69

Price and Availability

Size Price Availability Quantity
5.0mg USD 20.0 2 weeks
10.0mg USD 30.0 2 weeks
25.0mg USD 40.0 2 weeks
50.0mg USD 50.0 2 weeks
100.0mg USD 60.0 2 weeks
200.0mg USD 70.0 2 weeks
500.0mg USD 80.0 2 weeks
1.0g USD 90.0 2 weeks
2.0g USD 150.0 2 weeks
5.0g USD 250.0 2 weeks
10.0g USD 450.0 2 weeks
20.0g USD 850.0 2 weeks
50.0g USD 1450.0 2 weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: Bezafibrate; Benzofibrate; BM 15075; Bezalip; Bezatrol; Difaterol; Cedur; Bezafibratum

IUPAC/Chemical Name: 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid


InChi Code: InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 361.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Erratum: Systematic review and meta-analysis: bezafibrate in patients with
primary biliary cirrhosis [Erratum]. Drug Des Devel Ther. 2015 Nov 6;9:5947.
eCollection 2015. PubMed PMID: 26604692; PubMed Central PMCID: PMC4642802.

2: Liu X, Yang X, Chen X, Zhang Y, Pan X, Wang G, Ye Y. Expression Profiling
Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma. J
Cancer. 2015 Sep 20;6(12):1214-21. doi: 10.7150/jca.12191. eCollection 2015.
PubMed PMID: 26535062; PubMed Central PMCID: PMC4622851.

3: Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H,
Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C. Systematic review and
meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des
Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015.
PubMed PMID: 26491252; PubMed Central PMCID: PMC4599574.

4: Feng Y, Wang C, Liu Q, Meng Q, Huo X, Liu Z, Sun P, Yang X, Sun H, Qin J, Liu
K. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters
OAT1 and OAT3 in rats. Eur J Pharm Sci. 2016 Jan 1;81:119-28. doi:
10.1016/j.ejps.2015.10.008. Epub 2015 Oct 22. PubMed PMID: 26474691.

5: Courchesne-Loyer A, St-Pierre V, Hennebelle M, Castellano CA, Fortier M,
Tessier D, Cunnane SC. Ketogenic response to cotreatment with bezafibrate and
medium chain triacylglycerols in healthy humans. Nutrition. 2015
Oct;31(10):1255-9. doi: 10.1016/j.nut.2015.05.015. Epub 2015 Jun 6. PubMed PMID:

6: Honda A, Ikegami T, Matsuzaki Y. Anti-gp210 and anti-centromere antibodies for
the prediction of PBC patients with an incomplete biochemical response to UDCA
and bezafibrate. Hepatol Res. 2015 Aug;45(8):827-8. doi: 10.1111/hepr.12461.
PubMed PMID: 26205698.

7: Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, Sasahira N,
Tada M, Omata M, Koike K. Prospective study of bezafibrate for the treatment of
primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015
Oct;22(10):766-70. doi: 10.1002/jhbp.281. Epub 2015 Aug 21. PubMed PMID:

8: Licinio R, Facciorusso A, Castellaneta NM, Di Leo A. Combination Therapy of
Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis:
The End of the Steroid Era in Autoimmune Liver Diseases? Am J Gastroenterol. 2015
Jul;110(7):1086. doi: 10.1038/ajg.2015.163. PubMed PMID: 26148263.

9: Djouadi F, Habarou F, Le Bachelier C, Ferdinandusse S, Schlemmer D, Benoist
JF, Boutron A, Andresen BS, Visser G, de Lonlay P, Olpin S, Fukao T, Yamaguchi S,
Strauss AW, Wanders RJ, Bastin J. Mitochondrial trifunctional protein deficiency
in human cultured fibroblasts: effects of bezafibrate. J Inherit Metab Dis. 2015
Jun 25. [Epub ahead of print] PubMed PMID: 26109258.

10: Kobayashi J. How Does Bezafibrate Affect the Plasma LDL Cholesterol Levels? J
Atheroscler Thromb. 2015 Jul 23;22(7):658-9. doi: 10.5551/jat.ED007. Epub 2015
Mar 6. PubMed PMID: 25752495.

11: Hirose T, Teramoto T, Abe K, Taneyama T; J-BENEFIT study group. Determinants
of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients
with Diabetes. J Atheroscler Thromb. 2015 Jul 23;22(7):676-84. doi:
10.5551/jat.27425. Epub 2015 Mar 6. PubMed PMID: 25752494.

12: Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N,
Kakizaki S, Kusano M, Yamada M. A prospective randomized controlled study of
long-term combination therapy using ursodeoxycholic acid and bezafibrate in
patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol.
2015 Mar;110(3):423-31. doi: 10.1038/ajg.2015.20. Epub 2015 Mar 3. PubMed PMID:

13: Saha L, Bhandari S, Bhatia A, Banerjee D, Chakrabarti A. Anti-kindling Effect
of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in
Pentylenetetrazole Induced Kindling Seizure Model. J Epilepsy Res. 2014 Dec
31;4(2):45-54. eCollection 2014 Dec. PubMed PMID: 25625088; PubMed Central PMCID:

14: Vatanavicharn N, Yamada K, Aoyama Y, Fukao T, Densupsoontorn N, Jirapinyo P,
Sathienkijkanchai A, Yamaguchi S, Wasant P. Carnitine-acylcarnitine translocase
deficiency: Two neonatal cases with common splicing mutation and in vitro
bezafibrate response. Brain Dev. 2015 Aug;37(7):698-703. doi:
10.1016/j.braindev.2014.10.005. Epub 2014 Nov 1. PubMed PMID: 25459972.

15: Shiochi H, Ohkura T, Fujioka Y, Sumi K, Yamamoto N, Nakanishi R, Matsuzawa K,
Izawa S, Ohkura H, Inoue K, Ueta E, Kato M, Taniguchi S, Yamamoto K. Bezafibrate
improves insulin resistance evaluated using the glucose clamp technique in
patients with type 2 diabetes mellitus: a small-scale clinical study. Diabetol
Metab Syndr. 2014 Oct 17;6(1):113. doi: 10.1186/1758-5996-6-113. eCollection
2014. PubMed PMID: 25360162; PubMed Central PMCID: PMC4213459.

16: Ørngreen MC, Vissing J, Laforét P. No effect of bezafibrate in patients with
CPTII and VLCAD deficiencies. J Inherit Metab Dis. 2015 Mar;38(2):373-4. doi:
10.1007/s10545-014-9779-3. Epub 2014 Oct 21. PubMed PMID: 25331908.

17: Bastin J, Bonnefont JP, Djouadi F, Bresson JL. Should the beneficial impact
of bezafibrate on fatty acid oxidation disorders be questioned? J Inherit Metab
Dis. 2015 Mar;38(2):371-2. doi: 10.1007/s10545-014-9775-7. Epub 2014 Oct 14.
PubMed PMID: 25310995.

18: Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H. Biochemical
responses to bezafibrate improve long-term outcome in asymptomatic patients with
primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 2015
Jun;50(6):675-82. doi: 10.1007/s00535-014-0998-z. Epub 2014 Sep 20. PubMed PMID:

19: Shioya A, Takuma H, Yamaguchi S, Ishii A, Hiroki M, Fukuda T, Sugie H,
Shigematsu Y, Tamaoka A. Amelioration of acylcarnitine profile using bezafibrate
and riboflavin in a case of adult-onset glutaric acidemia type 2 with novel
mutations of the electron transfer flavoprotein dehydrogenase (ETFDH) gene. J
Neurol Sci. 2014 Nov 15;346(1-2):350-2. doi: 10.1016/j.jns.2014.08.040. Epub 2014
Aug 30. PubMed PMID: 25216552.

20: Gonçalves AG, Órfão JJ, Pereira MF. Ozonation of bezafibrate over ceria and
ceria supported on carbon materials. Environ Technol. 2015
Mar-Apr;36(5-8):776-85. doi: 10.1080/09593330.2014.961563. Epub 2014 Oct 3.
PubMed PMID: 25189707.